Urogen Pharma Ltd., of Ra'anana, Israel, said it closed its IPO of about 5.1 million shares priced at $13 apiece, including the exercise in full of the underwriters' option to purchase an additional 671,005 shares, resulting in gross proceeds of about $66.9 million.